|
1
|
Su D, Stamatakis L, Singer EA and
Srinivasan R: Renal cell carcinoma: molecular biology and targeted
therapy. Curr Opin Oncol. 26:321–327. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hitzerd SM, Verbrugge SE, Ossenkoppele G,
Jansen G and Peters GJ: Positioning of aminopeptidase inhibitors in
next generation cancer therapy. Amino Acids. 46:793–808. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wickström M, Larsson R, Nygren P and
Gullbo J: Aminopeptidase N (CD13) as a target for cancer
chemotherapy. Cancer Sci. 102:501–508. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ishii K, Usui S, Sugimura Y, Yoshida S,
Hioki T, Tatematsu M, Yamamoto H and Hirano K: Aminopeptidase N
regulated by zinc in human prostate participates in tumor cell
invasion. Int J Cancer. 92:49–54. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fontijn D, Duyndam MC, van Berkel MP,
Yuana Y, Shapiro LH, Pinedo HM, Broxterman HJ and Boven E:
CD13/Aminopeptidase N overexpression by basic fibroblast growth
factor mediates enhanced invasiveness of 1F6 human melanoma cells.
Br J Cancer. 94:1627–1636. 2006.PubMed/NCBI
|
|
6
|
Mina-Osorio P: The moonlighting enzyme
CD13: old and new functions to target. Trends Mol Med. 14:361–371.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Terauchi M, Kajiyama H, Shibata K, Ino K,
Nawa A, Mizutani S and Kikkawa F: Inhibition of APN/CD13 leads to
suppressed progressive potential in ovarian carcinoma cells. BMC
Cancer. 7:1402007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Martin-Padura I, Marighetti P, Agliano A,
Colombo F, Larzabal L, Redrado M, Bleau AM, Prior C, Bertolini F
and Calvo A: Residual dormant cancer stem-cell foci are responsible
for tumor relapse after antiangiogenic metronomic therapy in
hepatocellular carcinoma xenografts. Lab Invest. 92:952–966. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ichinose Y, Genka K, Koike T, Kato H,
Watanabe Y, Mori T, Iioka S, Sakuma A and Ohta M: NK421 Lung Cancer
Surgery Group: Randomized double-blind placebo-controlled trial of
bestatin in patients with resected stage I squamous-cell lung
carcinoma. J Natl Cancer Inst. 95:605–610. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wakita A, Ohtake S, Takada S, Yagasaki F,
Komatsu H, Miyazaki Y, Kubo K, Kimura Y, Takeshita A, Adachi Y,
Kiyoi H, Yamaguchi T, Yoshida M, Ohnishi K, Miyawaki S, Naoe T,
Ueda R and Ohno R: Randomized comparison of fixed-schedule versus
response-oriented individualized induction therapy and use of
ubenimex during and after consolidation therapy for elderly
patients with acute myeloid leukemia: the JALSG GML200 Study. Int J
Hematol. 96:84–93. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsukamoto H, Shibata K, Kajiyama H,
Terauchi M, Nawa A and Kikkawa F: Aminopeptidase N (APN)/CD13
inhibitor, Ubenimex, enhances radiation sensitivity in human
cervical cancer. BMC Cancer. 8:742008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu JW, Li CG, Huang XE, Li Y and Huo JG:
Ubenimex capsule improves general performance and chemotherapy
related toxicity in advanced gastric cancer cases. Asian Pac J
Cancer Prev. 12:985–987. 2011.PubMed/NCBI
|
|
13
|
Sugano O, Muto A, Kato M and Ono K: A case
of renal cell carcinoma with lymph node metastasis keeping
remission for five years by adjuvant immunotherapy with ubenimex.
Gan To Kagaku Ryoho. 30:1519–1522. 2003.(In Japanese). PubMed/NCBI
|
|
14
|
Saitoh Y, Koizumi K, Minami T, Sekine K,
Sakurai H and Saiki I: A derivative of aminopeptidase inhibitor
(BE15) has a dual inhibitory effect of invasion and motility on
tumor and endothelial cells. Biol Pharm Bull. 29:709–712. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mawrin C, Wolke C, Haase D, Krüger S,
Firsching R, Keilhoff G, Paulus W, Gutmann DH, Lal A and Lendeckel
U: Reduced activity of CD13/aminopeptidase N (APN) in aggressive
meningiomas is associated with increased levels of SPARC. Brain
Pathol. 20:200–210. 2010. View Article : Google Scholar
|
|
16
|
Inagaki Y, Tang W, Zhang L, Du G, Xu W and
Kokudo N: Novel aminopeptidase N (APN/CD13) inhibitor 24F can
suppress invasion of hepatocellular carcinoma cells as well as
angiogenesis. Biosci Trends. 4:56–60. 2010.PubMed/NCBI
|
|
17
|
Ishii K, Usui S, Sugimura Y, Yamamoto H,
Yoshikawa K and Hirano K: Inhibition of aminopeptidase N (AP-N) and
urokinase-type plasminogen activator (uPA) by zinc suppresses the
invasion activity in human urological cancer cells. Biol Pharm
Bull. 24:226–230. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sekine K, Fujii H and Abe F: Induction of
apoptosis by bestatin (ubenimex) in human leukemic cell lines.
Leukemia. 13:729–734. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sekine K, Fujii H, Abe F and Nishikawa K:
Augmentation of death ligand-induced apoptosis by aminopeptidase
inhibitors in human solid tumor cell lines. Int J Cancer.
94:485–491. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eum KH and Lee M: Crosstalk between
autophagy and apoptosis in the regulation of paclitaxel-induced
cell death in v-Ha-ras-transformed fibroblasts. Mol Cell Biochem.
348:61–68. 2011. View Article : Google Scholar
|
|
21
|
Natsumeda M, Aoki H, Miyahara H, Yajima N,
Uzuka T, Toyoshima Y, Kakita A, Takahashi H and Fujii Y: Induction
of autophagy in temozolomide treated malignant gliomas.
Neuropathology. 31:486–493. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Evangelisti C, Ricci F, Tazzari P,
Tabellini G, Battistelli M, Falcieri E, Chiarini F, Bortul R,
Melchionda F, Pagliaro P, Pession A, McCubrey JA and Martelli AM:
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR
inhibitors has cytotoxic effects in T-cell acute lymphoblastic
leukemia. Leukemia. 25:781–791. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Crowley LC, Elzinga BM, O’Sullivan GC and
McKenna SL: Autophagy induction by Bcr-Abl-expressing cells
facilitates their recovery from a targeted or nontargeted
treatment. Am J Hematol. 86:38–47. 2011. View Article : Google Scholar
|
|
24
|
Liang XH, Jackson S, Seaman M, Brown K,
Kempkes B, Hibshoosh H and Levine B: Induction of autophagy and
inhibition of tumorigenesis by beclin 1. Nature. 402:672–676. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mathew R, Kongara S, Beaudoin B, Karp CM,
Bray K, Degenhardt K, Chen G, Jin S and White E: Autophagy
suppresses tumor progression by limiting chromosomal instability.
Genes Dev. 21:1367–1381. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Karantza-Wadsworth V, Patel S, Kravchuk O,
Chen G, Mathew R, Jin S and White E: Autophagy mitigates metabolic
stress and genome damage in mammary tumorigenesis. Genes Dev.
21:1621–1635. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hashida H, Takabayashi A, Kanai M, Adachi
M, Kondo K, Kohno N, Yamaoka Y and Miyake M: Aminopeptidase N is
involved in cell motility and angiogenesis: its clinical
significance in human colon cancer. Gastroenterology. 122:376–386.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ikeda N, Nakajima Y, Tokuhara T, Hattori
N, Sho M, Kanehiro H and Miyake M: Clinical significance of
aminopeptidase N/CD13 expression in human pancreatic carcinoma.
Clin Cancer Res. 9:1503–1508. 2003.PubMed/NCBI
|
|
29
|
Tokuhara T, Hattori N, Ishida H, Hirai T,
Higashiyama M, Kodama K and Miyake M: Clinical significance of
aminopeptidase N in non-small cell lung cancer. Clin Cancer Res.
12:3971–3978. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kawamura J, Shimada Y, Kitaichi H, Komoto
I, Hashimoto Y, Kaganoi J, Miyake M, Yamasaki S, Kondo K and
Imamura M: Clinicopathological significance of aminopeptidase
N/CD13 expression in human gastric carcinoma.
Hepatogastroenterology. 54:36–40. 2007.PubMed/NCBI
|
|
31
|
Sørensen KD, Abildgaard MO, Haldrup C,
Ulhøi BP, Kristensen H, Strand S, Parker C, Høyer S, Borre M and
Ørntoft TF: Prognostic significance of aberrantly silenced ANPEP
expression in prostate cancer. Br J Cancer. 108:420–428. 2013.
View Article : Google Scholar : PubMed/NCBI
|
